Multiple myeloma (MM) has a double incidence in African-American (AA) than in non-AA patients and previous studies have shown a higher mortality in the former patient population. Here, we retrospectively analyzed the results of autologous stem cell transplantation (ASCT) in 38 AA and 32 non-AA consecutive patients. The two groups were comparable at diagnosis for age, stage of the disease, cytogenetic abnormalities, b 2 microglobulin and albumin blood levels, and plasma cell marrow infiltration. The rates of complete and partial response observed in AA and non-AA patients after induction chemotherapy (9 and 42 vs 13 and 33%) and at 2 months (31 and 25 vs 30 and 20%) following ASCT were similar. At 6 months after ASCT, a greater relapse rate was observed in non-AA patients (P ¼ 0.009). At a median follow-up of 26 months, AA patients had a greater event-free survival (P ¼ 0.02) than non-AA patients, whereas overall survival was comparable in the two groups. The initial finding that AA patients with MM, compared to non-AA patients, had more prolonged responses and comparable survival after ASCT suggests that intensified chemotherapy is equally effective in patients of various ethnicities.
Introduction
Multiple myeloma (MM) is a disorder of malignant plasma cells accumulating in the bone marrow that accounts for 10% of hematologic malignancies in the US. The overall annual incidence is 3-4/100 000. However, the incidence is increased in African-Americans (AA), being 9/100 000 in AA male and 6/100 000 in AA female subjects. 1 In the Surveillance Epidemiology and End Results (SEER) database, from 1973 to 1998, AA were shown to have double the risk of diagnosis and twice the mortality rate from MM. 2 Etiologies for the disparity have been investigated and despite some possible relationship to differences in socioeconomic status (SES), 2, 3 responses to immune challenges, 4, 5 increased body mass index 6, 7 and hereditary conditions due to AA having a higher frequency of the HLA-Cw2 allele, 7 no final demonstration has yet been found.
High-dose myeloablative treatment followed by autologous stem cell transplantation (ASCT) has proven superior to standard dose chemotherapy in the treatment of MM, significantly improving the response rate and survival of these patients. 8 However, there is no information available on the outcome of AA patients with MM undergoing ASCT.
In this study, we retrospectively analyzed the outcome of 70 consecutive MM patients, including 38 AA and 32 non-AA, who were treated at the University of Illinois at Chicago. Clinical responses to induction chemotherapy and to ASCT were analyzed in AA and non-AA patients and event-free survival (EFS) and overall survival (OS) estimates were also calculated in the two groups.
Patients, materials and methods

Patients
In this retrospective study, 70 consecutive patients (AA, n ¼ 38; non-AA, n ¼ 32) with MM receiving high-dose myeloablative therapy followed by ASCT at the University of Illinois at Chicago Medical Center from December 1999 to March 2004 were included without any selection. The protocol was approved by the institution's Institutional Review Board (IRB) before the chart review. Characteristics of AA and non-AA MM patients at diagnosis, including age, gender ratio, cytogenetic abnormalities, isotype, albumin and b 2 -microglobulin levels, skeletal involvement, stage of disease and plasma cell marrow infiltration, are shown in Table 1 . Parameters that were analyzed after treatment included serum and urine protein electrophoresis (SPEP and UPEP), as well as blood levels of hemoglobin (Hgb), calcium, creatinine, b 2 -microglobulin. A bone marrow biopsy and a radiological skeletal survey were also included in the post-induction and post-transplant restaging. Clinical responses were graded according to standard criteria described previously. 9 Response to ASCT was analyzed in the two groups at approximately 2 and 6 months after ASCT as well as at the last follow-up.
Transplantation
Peripheral blood stem cells (PBSC) were collected by leukapheresis procedures after treatment of the patients with mobilizing regimens. These regimens included the following: high-dose cyclophosphamide at 3 or 4 g/m 
Statistical analysis
Differences in the two groups were calculated by means of the Student's t-test and w 2 test. Event-free survival and OS estimates were obtained using the method of Kaplan and Meyer.
Results
Response rates
We initially analyzed the characteristics of AA and non-AA at diagnosis and observed that the two groups had comparable rates of patients with advanced disease, increased levels of b 2 microglobulin and cytogenetic abnormalities ( Table 1) . Both groups of patients had been homogeneously treated with induction regimens that consisted of the combination of vincristine, adriamycin and dexamethasone (VAD regimen) in 66% of patients in each group (Table 2) , as well as stem cell-mobilizing regimens, which consisted mostly of cyclophosphamidebased regimens (cyclophosphamide alone or CDEP regimen). High-dose melphalan was used as the conditioning regimen in 84% AA and 72% non-AA (P ¼ 0.2), whereas the other patients were treated with BCNU/melphalan before stem cell infusion (Table 3) .
We then analyzed the clinical response rates achieved in the two groups after induction chemotherapy and after ASCT. The results are shown in Figure 1 . After induction chemotherapy, complete remission (CR) and partial remission (PR) rates in AA (9 and 42%) were similar to non-AA (13 and 33%). Likewise, approximately 8 weeks post-ASCT, CR and PR rates were 31 and 25% in AA and 30 and 20% in non-AA. However, at 6 months post-ASCT, a greater number of non-AA patients showed a progression of the disease as compared to AA patients (75 vs 40%, P ¼ 0.009). At 6 months post-ASCT, this difference was not detected when only patients with cytogenetic abnormalities were analyzed. As expected, in fact, a high incidence of relapse was observed in these patients regardless of ethnicity.
Survival
At a median follow-up of 26 months (range: 1-89 months), 79% of AA and 69% non-AA were alive (P ¼ 0.3). Of the eight deaths in the AA group and 10 in the non-AA group, 16 were due to progression of the disease (six in AA and 10 in non-AA), whereas the transplant-related mortality was 2.9% (two patients with bacterial pneumonia and bacterial sepsis with disseminated intravascular coagulation (DIC), respectively). Consistent with the clinical findings at 6 months after ASCT, a significantly increased estimated median EFS was observed in AA compared to non-AA patients (21 vs 12 months, P ¼ 0.02). Among the non-AA patients, 75% Hispanics relapsed within 12 months after transplant as opposed to 33% Caucasians. However, the difference was not statistically significant (P ¼ 0.1).
Relapsed patients either received a second ASCT, or an allogeneic stem cell transplant, or were treated with salvage therapies. A trend for a more prolonged OS was observed in the AA group compared to non-AA patients (64 vs 39 months). However, the difference was not statistically significant (P ¼ 0.19) (Figure 2 ). These findings suggest that AA patients with MM have at least the same survival probability as non-AA patients.
Discussion
In this study, we observed that AA patients with MM have a more prolonged response to high-dose chemotherapy followed by hematopoietic stem cell infusion than non-AA patients.
The influence of ethnicity has been previously demonstrated in outcome analyses of cancer patients. 2 In a recent study investigating the role of ethnicity in hematopoietic stem cell transplantation, 10 AA patients were shown to have a higher mortality rate in allogeneic, but not autologous transplantation. However, in their analysis of Differences in response rates between African-American (AA) and non-AA patients were not significant after induction chemotherapy and 2 months following ASCT. At 6 months after transplant, there was a significant increase in relapses among non-AA patients (P ¼ 0.009). ASCT, whereas there were 1366 white patients, only 37 black patients were included. Multiple myeloma is annually diagnosed in double the number of AA than non-AA patients. 11 More importantly, previous studies have reported inferior survival rates in black compared to white MM patients. However, these studies were mostly performed before ASCT became standard of treatment.
2 It thus remains to be determined whether modern treatments for MM may result in different response rates and/or survival in AA and non-AA MM patients. As high-dose chemotherapy followed by ASCT has been proven superior to standard chemotherapy, 8, 12 we addressed the question of whether, in patients homogenously treated with conventional induction therapy followed by ASCT, there would be a different outcome between AA and non-AA MM patients.
We retrospectively analyzed 70 patients who were consecutively transplanted at our institution, including 38 AA and 32 non-AA patients. The first observation was that the two groups did not differ at diagnosis, particularly with regard to prognostic factors such as b 2 -microglobulin level, cytogenetic abnormalities or albumin level. Then, they equally responded to induction chemotherapy and ASCT, suggesting that ethnicity is unlikely to correlate with sensitivity to chemotherapy in MM. However, it was surprising to observe that the clinical response achieved after ASCT, determined as response rate at 6 months after ASCT and EFS estimate, had a significantly longer duration in AA compared to non-AA. This may not be in contrast with the fact that we and others 10, 13 could not detect a significant advantage in survival, which, however, in our study was 64 months in AA and 39 months in non-AA. In fact, the OS reflects also the efficacy of multiple salvage strategies, encompassing a second ASCT, allogeneic SCT or treatment with new agents such as thalidomide and/or bortezomib. Our results suggesting that AA with MM might have better results with one ASCT than non-AA patients will need to be confirmed in larger transplant registries where the analysis of a greater number of AA and non-AA patients treated with comparable protocols can be performed. In particular, it will be also important to analyze, in larger series, the results in Hispanic patients, who showed a trend for a worse EFS in this study. Nevertheless, our initial findings do indicate that intensified chemotherapy with ASCT results in at least comparable survival in MM patients with different ethnicity. As new treatments are now available to MM patients, both as induction 14, 15 and salvage treatment, [15] [16] [17] [18] future studies on the clinical outcome as well as on pharmacokinetics, bioavailability, sensitivity, socioeconomic and environmental factors in AA and non-AA MM patients will have the opportunity to determine the influence of ethnicity on the treatment outcome with these new agents and to elucidate the potential causes underlying the ethnic differences.
